Background/objective: To evaluate the psychological predictors of the outcome of real-life experience with the anti-CGRP monoclonal antibody Erenumab in a 1-year follow-up in chronic migraine (CM). The gene discussed is CALCA; the disease is cutaneous mastocytosis.